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PRESERVATION OF PULMONARY DIFFUSING CAPACITY WITH ORAL BE-
CLOMETHASONE DIPROPIONATE: RESULTS FROM TWO RANDOMIZED,
PLACEBO-CONTROLLED TRIALS IN ALLOGENEIC GRAFT RECIPIENTS
Chien, J.W., Gooley, T., Sakai, M., Schoch, H.G., McDonald, G.B. Fred
Hutchinson Cancer Research Center, Seattle, WA.
Randomized trials show that oral BDP allows rapid tapering of
prednisone while controlling gastrointestinal GVHD following al-
logeneic hematopoietic cell transplant and results in better out-
comes (Blood 2007;109:4557–63). In reviewing adverse event
data, we noted fewer pulmonary infiltrates in the BDP arm, perhaps
because oral BDP is metabolized in the gut to the potent immuno-
suppressive metabolite 17-beclomethasone monopropionate (17-
BMP), some of which is transported via the portal circulation and
pulmonary artery directly to the lung. To test the hypothesis that
17-BMP preserved lung function after HCT, we reviewed prospec-
tive pulmonary function tests in 120 randomized patients who had
been randomized at FHCRC.
Methods:Two studies had randomized patients with GI GVHD
to a 10-day induction course of prednisone 1 mg/kg/d for 10 days
plus either oral BDP 8 mg/d or placebo. Patients whose symptoms
were under control at study day 10 had prednisone tapered rapidly
but study drug was continued for 30–50 days. GVHD treatment
failures were treated with prednisone 1–2 mg/kg/d. Change in
lung function was assessed by comparing pulmonary function tests
(PFTs: FEV1, FVC, TLC, DLCO) performed prior to start of con-
ditioning to those obtained post-transplant at day 80, blinded to
randomization assignment. Results: Sixty patients had been ran-
domized to oral BDP and the same number to placebo. Serial
PFTs at day 80 were available from 44 and 50 patients on placebo
and BDP, respectively. Significantly fewer patients randomized to
BDP (55%) had deterioration of diffusing capacity by transplant
day 80, compared to placebo (79%), p 5 0.02. No such differences
were noted in other PFT parameters. Conclusions: These data
suggest that oral BDP may have a protective effect on early decline
in pulmonary diffusing capacity, which commonly occurs by day 80
after transplant because of interstitial lung injury. We hypothesize
that preservation of diffusing capacity was due to delivery of the po-
tent immunosuppressive metabolite 17-BMP to the lungs via GI
mucosa, portal vein, and pulmonary artery.
Proportion of patients whose PFTs decreased from pre-HCT baseline to
transplant day 80 and magnitude of changes, by randomization
assignment (chi square test)
Baseline toHCT day 80
(# decreased/total #)Magnitude of % change
(mean, range)PFT Placebo BDP P Placebo BDPDLCO 32/44 (79%) 27/49 (55%) .02 27.95 (240, 123) 10.57 (274, 1115)FVC 24/44 (55%) 25/50 (50%) .66 21.85 (220, 116) 10.34 (230, 135)TLC 25/42 (60%) 29/50 (58%) .88 21.67 (220, 123) 11.41 (225, 157)FEV1 21/44 (48%) 25/50 (50%) .83 20.55 (225, 1109) 11.61 (227, 134)8
FACTORS AFFECTING 100-DAY AND 1-YEAR MORTALITY FOLLOWING
MYELOABLATIVE SINGLE-UNIT CORD BLOOD TRANSPLANTATION IN
ADULTS AND ADOLESCENTS: A COMPREHENSIVE META-ANALYSIS OF
CIBMTR, NCBP AND EUROCORD
Cohen, Y.C.1, Scaradavou, A.2, Stevens, C.E.2, Rubinstein, P.2,
Gluckman, E.3, Pacheco, D.3, Eapen, M.4, Horowitz, M.M.4,Shpall, E.J.5, Laughlin, M.J.6, Nagler, A.7, Daniely, Y.1,
Barishev, R.8, Olmer, L.8, Freedman, L.S.8. 1Gamida Cell Ltd., Jerusa-
lem, Israel; 2New York Blood Center, NY, NY; 3Hospital Saint Louis,
Paris, France; 4Medical College ofWisconsin,Milwaukee,WI; 5MDAn-
derson Cancer Center, Houston, TX; 6Cleveland Cord Blood Center,
Cleveland, OH; 7Sheba Medical Center, Tel Hashomer, Israel; 8Gertner
Institute for Epidemiology and Health Policy Research, Tel Hashomer,
Israel.
A retrospective meta-analysis was conducted to examine factors
affecting mortality following myeloablative, single-unit cord blood
transplantation (CBT) for hematological malignancies in adoles-
cents and adults. Data was collected from three cord-blood trans-
plant registries, Center for International Blood and Marrow
Transplant Research (CIBMTR), National Cord Blood Program
(NCBP) and Eurocord, and included all records of single, unmanip-
ulated, first myeloablative allogeneic CBT conducted in North
America or Europe from 1995 to 2005, with HLA match $4/6, in
patients with acute leukemia, chronic myeloid leukemia, myelodys-
plastic syndrome or lymphoma aged 12 to 55, for which 100-day
survival data was available. Data was pooled after screening for spec-
ified eligibility criteria, creation of common classifications, check-
ing for integrity and consistency, and removal of duplicates.
Analysis involved comparison of survival outcomes according to
known and exploratory prognostic factors. These covariates were
used to build logistic regression models for 100-day and 1-year
mortality. Five hundred and fourteen of 742 potential records
were found to meet eligibility criteria and were included in the
meta-analysis. Overall 100-, 180-day and 1-year mortalities (Ka-
plan-Meier) were 44%, 56% and 68%, respectively with no signif-
icant heterogeneity across registries. Some heterogeneity was
observed in the prognostic factors. Multivariate analysis showed
cell dose\ 2.5  107/Kg (Odds Ratio 2.74, p\ 0.0001), disease
stage (p 5 0.04), positive CMV sero-status (OR 1.46 p 5 0.056),
age (p5 0.002), female gender (OR 1.45, p5 0.059) and transplant
center with less CBT experience (contribution of\10 registry re-
cords, OR 2.02, p 5 0.0007) to be associated with higher 100-day
mortality; A multivariate model predictive of 1-year mortality in-
cluded similar covariates: cell dose (OR 1.66, p 5 0.011), disease
stage (p 5 0.03), CMV (OR 2.25 p\ 0.0001), age (p 5 0.02) and
center experience (OR 2.25, p 5 0.0002). Transplant year was not
independently predictive of mortality in either of these models.
This is the first meta-analysis to pool records from three major
CBT registries in the US and Europe. Despite differences in prac-
tice patterns, survival data showed remarkable homogeneity. The
resulting models will be used in the analysis of the Pivotal Study
of StemEx; transplantation of cord blood expanded ex vivo with
a copper chelator along with the non-manipulated fraction of the
same cord blood unit.9
RISK FACTORS ASSOCIATED WITH GRAFT FAILURE AFTER UMBILICAL
CORD BLOOD TRANSPLANTATION (UCBT): A SINGLE CENTER ANALYSIS
IN 539 PATIENTS
Doshi, K., Brunstein, C.G., Cao, Q., Wagner, J.E. University of Minne-
sota, Minneapolis, MN.
UCBT has proved to be a viable alternative for pediatric and adult
patients who do not have an HLA matched related or unrelated do-
nor. However, the incidence of graft failure (GF), an often fatal
complication, has been reported to be as high as 30% in some series.
Therefore, we attempted to identify potential risk factors associated
with GF in 539 patients (adult, n 5 297; pediatric, n 5 242) trans-
planted with UCB at University of Minnesota between 1994–2006.
Patients received one (n 5 261) or two (n 5 278) UCB units after
a myeloablative (MA, n 5 338) or reduced intensity (RIC, n 5
201) conditioning regimen for malignant (n 5 418) or non-malig-
nant (n 5 121) disease. GF was defined as evidence of \5%5
6 Oral Presentationschimerism or failure to achieve neutrophil recovery by day 42. Me-
dian patient age and weight was 22 years (r: 0–69) and 61 kg (r: 4–
149 kg), respectively, with 66 having had a prior autologous trans-
plant. Time from diagnosis to transplant was 13.3 months (1.26–
250 months), 57 patients were CMV1, 186 received a sex-matched
graft, 132 ABO-matched, 168 minor ABO-MM, and 229 major
ABO-MM. Median graft cell doses were 3.8  107 nucleated cells
(NC)/kg (r: 0.7–48.9) and 4.6  105 CD34/kg (r:0.4–275.3).
Fifty-seven received 6/6 HLA-matched units, 196 received at least
one 5/6 matched unit and 286 received at least one 4/6 matched
unit. GF was observed in 43/338 (12.7%) after MA and 36/201
(17.9%) after RI UCBT. Risk factors associated with GF in logistic
regression were transplantation of HLA mismatched units (5/6
match, OR 9.13, 95%CI, 1.19–70.38; 4/6 match, OR 11.66,
95%CI 1.53–89.00; p\ .01), treatment of non-malignant disease
(OR 2.55, 95%CI, 1.35–4.81, p\ .01), low CD34 cell dose (top
low quartile OR 2.33, 95%CI, 1.07–5.05; bottom low quartile,
OR 3.11, 95%CI, 1.44–6.70; p \ .01), and use of a RIC (OR
2.40, 95%CI 1.35–4.26; p\ .01). Patients who received a prior au-
tologous transplant had lower odds of GF (OR 0.12, 95%CI, 0.03–
0.52, p\ .01). Factors not impacting risk of GF were recipient age,
sex-match, ABO-match, CMV serostatus, performance status, diag-
nosis, disease risk, interval from diagnosis to transplant, NC dose,
and CD3 cell dose. In addition to CD34 cell dose and HLA match,
patients with non malignant disease and recipients of a RIC are at
higher risk of GF. These results support the need for greater invest-
ment in banking UCB with larger cell doses and HLA diversity and
development of improved strategies for overcoming GF in high risk
patient populations.10
COSTIMULATORY BLOCKADE (CSB) DURING MIXED LYMPHOCYTE RE-
ACTION (MLR) PREVENTS IL27 UPREGULATION AND SIGNALLING
Gorgun, G.1, Philpot, P.A.1, Naxerova, K.2, Kohane, I.S.2,
Nadler, L.M.1, Guinan, E.C.1,2. 1Dana-Farber Cancer Institute; 2Chil-
dren’s Hospital, Boston, MA.
Numerous methods for selectively depleting or manipulating al-
loantigen (alloAg) specific CD4 T cells (CD4 T) are being studied
for their potential in improving transplant outcomes by limiting
GVHD or graft rejection. However, their effects on off-target
CD4 T cellular pathways and functions and on other PBMC are
not well described. We used global gene expression profiling
(GEP) to elucidate the molecular impacts on bystander PBMC after
inducing alloAg specific CD4 T anergy by CD28:B7 costimulatory
signal blockade (CSB) via humanized anti B7.1/B7.2 MoAbs. Mim-
icking our ex vivo clinical anergization protocol, PBMC were iso-
lated from fully-HLA mismatched healthy donors (n 5 12) to
perform ex vivo primary MLR1/-anti B7.1/B7.2 MoAbs. CSB in-
hibited mean proliferation by 73% after 72 h of MLR. GEP was
performed using Affymetrix hu133 plus2 chips on monocytes
(Mo), CD4 and CD8 T, B and NK cells purified from these
MLR. Despite low published frequencies (1–10%) of alloAg-spe-
cific CD4 T, we detected global gene expression variance (P \
0.05) between CD4 T isolated from MLR1/-CSB suggesting ef-
fects on non-alloAg specific CD4 T. Analysing these differentially
expressed genes by cellular pathway highlighted those active in
cell proliferation and differentiation. Particularly, differences in
IL27 signaling molecules in Mo and CD4 T were prominent.
IL27, a heterodimer of p28 and EBV-Induced gene 3 (EBI3) and
IL12 family member produced by APC, signals through its recep-
tor, IL27R, on CD4 T. IL27 regulates adaptive immunity by con-
trolling T cell proliferation, Th1 differentiation and IFNg
synthesis. Both p28 and EBI3 gene and protein expression levels
were decreased in Mo from MLR1CSB. After CSB, CD4 T showed
decreased IL27R and STAT3 expression and inactivation of
pSTAT1 and NFkB. Intracytoplasmic cytokine (ICC) analysis
showed decreased IL2 and IFNg expression in CD4 T, decreased
IL15 and increased IL10 in Mo from MLR1CSB supporting the
negative effect of IL27 on Th1 differentiation. These data suggest
that CD28:B7 signaling during MLR is required for Mo production
of IL27. Decreased expression of IL27R, pSTAT1 and NFkB after
CSB may contribute to CD4 T alloAg anergy induction by sup-pressing effector cytokines and Th1 differentiation. CD28:B7 mod-
ulation of IL27 and IL27R emphasizes that targeted therapies used
in the complex environment of human PBMC may have effects un-
predicted by in vitro clonal systems, which may be important in the
functional outcome of the intervention.11
RISK FACTOR ANALYSIS FOR THE DEVELOPMENT OF RESTRICTIVE AND
OBSTRUCTIVE PULMONARY FUNCTION CHANGES AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION
Rabanus, R., Hahn, J., Andreesen, R., Holler, E., Hildebrandt, G.C.
University of Regensburg Medical Center, Regensburg, Germany.
Pulmonary complications after allogeneic stem cell transplanta-
tion (allo-SCT) significantly contribute to morbidity and mortality.
We analyzed 207 patients receiving allo-SCT at our institution be-
tween 1998 and 2005 for the development of restrictive (PRC) and
obstructive (POC) pulmonary function changes. Pulmonary func-
tion tests (PFT) were performed before and routinely every 3 to 6
months after allo-SCT. After follow-up .2 years, PFTs were ob-
tained yearly. 142 patients were included according to the availabil-
ity of PFTs; 65 patients were excluded due to early mortality and/or
the lack of PFT data. PRC were defined as a forced vital capacity
(FVC) at least once#90% of pre-transplant values, POC as a forced
expiratory volume (FEV1) at least once #80% of baseline. Median
time of follow-up was 1071 days (107–2924). For PRC, median time
of first onset was at 180 days (30–1482) and for POC at 270 days
(60–1800) after allo-SCT. The cumulative incidence for PRC was
70.7% and for POC 34.2%. Risk factor analysis included patient/
donor age and gender, type of transplant, stem cell source, condi-
tioning regimen intensity, TBI, T cell depletion, pretransplant-
CMV serology of donor and recipient, acute (aGVHD) and chronic
GVHD (cGVHD) and previous thoracic irradiation.
In univariate analysis, positive patient CMV serology was associ-
ated with the development of both PRC (p 5 0.05) and POC (p 5
0.005), whereas CMV immunity of the donor affected only the risk
of POC (p5 0.002). In addition, the cumulative incidence of POC
rose to 57.3% when both donor and recipient had positive pretrans-
plant anti-CMV immunity (p 5 0.0002) and to 51.4% in patients
with proven CMV reactivation (p 5 0.1). cGVHD increased the
risk of POC (p 5 0.0045) but not of PRC (p 5 0.127). Risk factors
for PRC but not POC were bone marrow derived stem cells (p 5
0.045) and female patient gender (p 5 0.057). In multivariate anal-
ysis, cGVHD (p5 0.037; HR 2.3 [1.1–5.0]), anti-CMV IgG positiv-
ity of the donor only (p 5 0.026; HR 2.3 [1.1–5.29]) and of both
donor and recipient combined (p5 0.004; HR 3.7 [1.5–9.3] were in-
dependent risk factors for POC, the latter also being the only inde-
pendent risk factor identified for PRC. Therefore, our data confirm
the previously described association between cGVHD and the de-
velopment of pulmonary obstructive changes. In addition, this anal-
ysis strengthens the concept, that anti-CMV immunity and CMV
reactivation contribute to pulmonary function impairment after
allo-SCT.12
UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) FOR TRANSFU-
SION-DEPENDENT THALASSEMIA – A CIBMTR AUDITED RETROSPEC-
TIVE ANALYSIS OF 51 CONSECUTIVE PATIENTS
Jaing, T.-H.1, Tan, P.2, Rosenthal, J.3, Chan, L.L.4, Lin, H.-P.5,
Tan, P.-L.6, Nademanee, A.3, Karanes, C.3, Gjertson, D.7, Wang, B.8,
Petz, L.8, Chow, R.8. 1Chang Gung Children’s Hospital & University,
Linko, Taiwan; 2Mount Elizabeth Hospital, Singapore; 3City of Hope
National Medical Center, Duarte, CA; 4University of Malaya Medical
Center, Kuala Lumpur, Malaysia; 5Subang Jaya Medical Center, Ma-
laysia; 6National University Hospital, Singapore; 7UCLA School of Pub-
lic Health, Los Angeles, CA; 8StemCyte International Cord Blood Center,
Arcadia, CA.
UCBT offers a cure for thalassemia and has advantages as a stem
cell source for minorities where thalassemia is prevalent, but cell
